Clinical testing of new antimalarial compounds.

Area of Science:

• Pharmacology
• Infectious Diseases
• Medicinal Chemistry

Background:

• Malaria remains a significant global health challenge, particularly infections caused by drug-resistant Plasmodium falciparum.
• The development of novel antimalarial drugs is crucial to combatting malaria.
• The US Army Antimalarial Drug Development Program has been actively screening chemical compounds for antimalarial properties.

Purpose of the Study:

• To identify and evaluate novel chemical compounds with potent antimalarial activity.
• To advance promising drug candidates through preclinical and clinical trials.
• To address the urgent need for effective treatments against drug-resistant malaria strains.

Main Methods:

• Screening of over 200,000 chemical compounds for antimalarial activity.
• Extensive animal testing to select promising candidates.
• Clinical trials in human subjects to assess safety and efficacy.

Main Results:

• 26 compounds were selected for clinical study after animal testing.
• 7 compounds completed clinical trials and are in field evaluation.
• 4 compounds are currently undergoing clinical trials, with 2 awaiting testing.
• Two compounds, WR 33 063 and WR 30 090, demonstrated superior activity against drug-resistant Plasmodium falciparum.
• Additional potent compounds are undergoing human subject testing.

Conclusions:

• The US Army's drug development program has identified highly effective antimalarial compounds.
• WR 33 063 and WR 30 090 represent significant advancements in treating drug-resistant malaria.
• Ongoing clinical evaluations suggest the potential for new, potent antimalarial therapies.